The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), in partnership with the Ann ...

Torqur AG, subsidiary of Swiss Rockets incubator and a clinical-stage company advancing targeted therapies in oncodermatology and oncology, announced the results of the full Phase 2 proof-of-concept ...

Researchers at Zhejiang University and Zhongshan Institute for Drug Discovery have discovered phosphatidylinositol 3-kinase δ (PI3Kδ) and mammalian target of rapamycin (mTOR; FRAP1) dual inhibitors ...

Kazia Therapeutics Ltd. raised AU$50 million (US$33.15 million) in a private placement of equity securities to advance lead candidate paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor in clinical ...

Randomized Phase III Study of Gemcitabine and Vinorelbine Versus Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer: From the German and Swiss Lung Cancer ...

Mammalian target of rapamycin (mTOR) inhibitors could be associated with acute nephrotoxicity, according to French researchers. The team describes 4 cancer patients who developed severe acute kidney ...

Circulating kidney injury molecule-1 (KIM-1) in association with kidney injury biomarkers and outcomes in metastatic renal cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Am J Health Syst Pharm. 2010;67(24):2095-2106. The second mTOR complex, mTORC2, contains mTOR, mLST8, and several unique proteins, including rictor (rapamycin-insensitive companion of mTOR). Rapamycin ...